Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.
Jean-Yves ReginsterEdward CzerwinskiKrzysztof WilkPrzemysław BorowyAnna StrzeleckaTomasz BudlewskiMonika Janowska-MausKrzysztof SzymanowskiJoanna KwiatekSvitlana PostolAiri PõderJerzy SupronikSungHyun KimJeeHye SuhNooRi HanNaHyun KimSeoHee BaeStuart L SilvermanPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)
CT-P41 was equivalent to US-denosumab in women with postmenopausal osteoporosis, with respect to primary efficacy and PD endpoints.